FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018657706> ?p ?o ?g. }

• W2018657706 endingPage "1387" @default.
• W2018657706 startingPage "1381" @default.
• W2018657706 abstract "This study assessed the usefulness of serial measurements of bone turnover markers in men with metastatic prostate cancer treated with zoledronic acid to detect disease progression.Serum measurements of total alkaline phosphatase (tALP), bone-specific alkaline phosphatase (bALP), cross-linked N-terminal (NTx) and cross-linked C-terminal (CTx) telopeptides of type I collagen, amino-terminal procollagen propeptides of type I collagen (PINP), C-terminal telopeptides of type I collagen (ICTP), and prostate-specific antigen (PSA) were performed in 77 prostate cancer patients suffering from bone metastases and treated with zoledronic acid up to 15 mo. Fifty patients were with and 27 patients without objective evidence of metastatic bone progression during the administration of zoledronic acid.The baseline bone marker concentrations were not significantly different between the groups. After administration of zoledronic acid all bone markers except of ICTP decreased compared with baseline. CTx showed the greatest decrease. In patients with metastatic bone progression PINP, tALP, bALP, and ICTP were significantly higher at weeks 24, 36, 48, and 60 after starting treatment with zoledronic acid compared with patients without progression. In addition to the information of prostate-specific antigen as a monitoring parameter, the bone formation marker showed a better distinction between patients with and without disease progression.Selected bone turnover markers provide valuable information regarding progression of bone metastasis in men with metastatic prostate cancer under bisphosphonate therapy. The clinical impact should be confirmed in prospective randomised studies." @default.
• W2018657706 created "2016-06-24" @default.
• W2018657706 creator A5000710774 @default.
• W2018657706 creator A5020617039 @default.
• W2018657706 creator A5034510651 @default.
• W2018657706 creator A5035279287 @default.
• W2018657706 creator A5044666749 @default.
• W2018657706 creator A5057031487 @default.
• W2018657706 creator A5058301129 @default.
• W2018657706 creator A5060509577 @default.
• W2018657706 creator A5061510459 @default.
• W2018657706 creator A5065289402 @default.
• W2018657706 creator A5078058786 @default.
• W2018657706 date "2007-11-01" @default.
• W2018657706 modified "2023-10-18" @default.
• W2018657706 title "Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression" @default.
• W2018657706 cites W1517801548 @default.
• W2018657706 cites W1532955823 @default.
• W2018657706 cites W1959778450 @default.
• W2018657706 cites W1963592300 @default.
• W2018657706 cites W1974568982 @default.
• W2018657706 cites W1977670767 @default.
• W2018657706 cites W1982915376 @default.
• W2018657706 cites W2002907172 @default.
• W2018657706 cites W2003251793 @default.
• W2018657706 cites W2005398724 @default.
• W2018657706 cites W2014006626 @default.
• W2018657706 cites W2033712867 @default.
• W2018657706 cites W2043471712 @default.
• W2018657706 cites W2046750802 @default.
• W2018657706 cites W2058681718 @default.
• W2018657706 cites W2058766023 @default.
• W2018657706 cites W2060700125 @default.
• W2018657706 cites W2080041465 @default.
• W2018657706 cites W2095170176 @default.
• W2018657706 cites W2104923745 @default.
• W2018657706 cites W2115962082 @default.
• W2018657706 cites W2162827359 @default.
• W2018657706 cites W2170565025 @default.
• W2018657706 cites W2327350066 @default.
• W2018657706 cites W2607028219 @default.
• W2018657706 doi "https://doi.org/10.1016/j.eururo.2007.02.033" @default.
• W2018657706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17321667" @default.
• W2018657706 hasPublicationYear "2007" @default.
• W2018657706 type Work @default.
• W2018657706 sameAs 2018657706 @default.
• W2018657706 citedByCount "62" @default.
• W2018657706 countsByYear W20186577062012 @default.
• W2018657706 countsByYear W20186577062013 @default.
• W2018657706 countsByYear W20186577062014 @default.
• W2018657706 countsByYear W20186577062015 @default.
• W2018657706 countsByYear W20186577062017 @default.
• W2018657706 countsByYear W20186577062018 @default.
• W2018657706 countsByYear W20186577062019 @default.
• W2018657706 countsByYear W20186577062021 @default.
• W2018657706 countsByYear W20186577062022 @default.
• W2018657706 crossrefType "journal-article" @default.
• W2018657706 hasAuthorship W2018657706A5000710774 @default.
• W2018657706 hasAuthorship W2018657706A5020617039 @default.
• W2018657706 hasAuthorship W2018657706A5034510651 @default.
• W2018657706 hasAuthorship W2018657706A5035279287 @default.
• W2018657706 hasAuthorship W2018657706A5044666749 @default.
• W2018657706 hasAuthorship W2018657706A5057031487 @default.
• W2018657706 hasAuthorship W2018657706A5058301129 @default.
• W2018657706 hasAuthorship W2018657706A5060509577 @default.
• W2018657706 hasAuthorship W2018657706A5061510459 @default.
• W2018657706 hasAuthorship W2018657706A5065289402 @default.
• W2018657706 hasAuthorship W2018657706A5078058786 @default.
• W2018657706 hasConcept C121608353 @default.
• W2018657706 hasConcept C126322002 @default.
• W2018657706 hasConcept C126894567 @default.
• W2018657706 hasConcept C143998085 @default.
• W2018657706 hasConcept C170033053 @default.
• W2018657706 hasConcept C2776169692 @default.
• W2018657706 hasConcept C2776235491 @default.
• W2018657706 hasConcept C2776326535 @default.
• W2018657706 hasConcept C2776490512 @default.
• W2018657706 hasConcept C2776541429 @default.
• W2018657706 hasConcept C2777251235 @default.
• W2018657706 hasConcept C2777783956 @default.
• W2018657706 hasConcept C2779013556 @default.
• W2018657706 hasConcept C2780192828 @default.
• W2018657706 hasConcept C2780644872 @default.
• W2018657706 hasConcept C2781406297 @default.
• W2018657706 hasConcept C71924100 @default.
• W2018657706 hasConceptScore W2018657706C121608353 @default.
• W2018657706 hasConceptScore W2018657706C126322002 @default.
• W2018657706 hasConceptScore W2018657706C126894567 @default.
• W2018657706 hasConceptScore W2018657706C143998085 @default.
• W2018657706 hasConceptScore W2018657706C170033053 @default.
• W2018657706 hasConceptScore W2018657706C2776169692 @default.
• W2018657706 hasConceptScore W2018657706C2776235491 @default.
• W2018657706 hasConceptScore W2018657706C2776326535 @default.
• W2018657706 hasConceptScore W2018657706C2776490512 @default.
• W2018657706 hasConceptScore W2018657706C2776541429 @default.
• W2018657706 hasConceptScore W2018657706C2777251235 @default.
• W2018657706 hasConceptScore W2018657706C2777783956 @default.
• W2018657706 hasConceptScore W2018657706C2779013556 @default.

• next